AB Enzymes Xylanase Variants - Patent US12600960B2
Summary
The USPTO granted Patent US12600960B2 to AB Enzymes Finland Oy for xylanase variant polypeptides comprising amino acid sequences with at least 79% but less than 100% identity to SEQ ID NO: 1, featuring at least one disulfide bridge and amino acid substitutions at positions 23 and/or 28. The patent covers the variant polypeptide, fusion proteins, enzyme compositions, recombinant host cells for production, and methods of use.
What changed
The USPTO issued Patent US12600960B2 to AB Enzymes Finland Oy for modified xylanase enzymes. The granted patent protects variant polypeptides having at least 79% but less than 100% amino acid sequence identity with SEQ ID NO: 1 (amino acids 1-191), containing at least one disulfide bridge between Cys residues and specific substitutions at positions 23 and/or 28. The patent claims 20 items covering the variant polypeptide, fusion proteins, enzyme compositions, recombinant host cells, and methods of using the variant for xylan degradation.
Inventors include Marja Paloheimo, Kari Juntunen, Ossi Turunen, Pihla Ahola, Pasi Taipalus, Eugen Müller, Jukka Savolainen, Kim Langfelder, and Terhi Puranen. The patent application (18269907) was filed December 23, 2021. Parties seeking to use similar enzyme engineering approaches for industrial xylanase applications should review this patent to assess potential licensing needs or design-around considerations.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Xylanase variants
Grant US12600960B2 Kind: B2 Apr 14, 2026
Assignee
AB Enzymes Finland Oy
Inventors
Marja Paloheimo, Kari Juntunen, Ossi Turunen, Pihla Ahola, Pasi Taipalus, Eugen Müller, Jukka Savolainen, Kim Langfelder, Terhi Puranen
Abstract
A variant polypeptide of xylanase, and a fusion protein and an enzyme composition comprising the variant polypeptide, a recombinant host cell for production of the variant polypeptide, methods for using it and its use, is disclosed comprising an amino acid sequence having at least 79%, but less than 100% amino acid sequence identity with amino acids 1-191 of SEQ ID NO: 1, wherein the amino acid sequence has xylanase activity, at least one disulfide bridge between two Cys residues in the 1-191 amino acid region, and an amino acid substitution at the position 23 or 28, or at the positions 23 and 28, the positions corresponding to the positions 23 and 28 of the SEQ ID NO: 1.
CPC Classifications
C12N 9/2482 C12N 15/80 A23K 20/189 A23K 10/14 A23K 50/10 C12Y 302/01008 D21C 9/1036 D21C 5/005 C07K 2319/02 C07K 2319/50 C12P 19/02 C12P 19/14
Filing Date
2021-12-23
Application No.
18269907
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.